Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
News|Articles|November 30, 2016
Agilent Technologies Opens Technology Center in California
Author(s)Pharmaceutical Technology Editors
Agilent’s new facility in Folsom, California includes laboratory, order fulfilment, and warehousing space.
Agilent Technologies opened a new, $14.7-million, 53,000-ft2 Technology Center in Folsom, California adjacent to Agilent's existing facility, the company announced on Nov. 30, 2016. The new facility, which will house approximately 60 additional staff, expands Agilent’s capabilities for chromatography consumables and hardware. The facility includes a customer applications laboratory and collaboration space, as well as facilities for providing the company’s scientific consumables and supplies. In particular, the new Folsom facility will support Agilent’s new Intuvo 9000 GC system and consumables products for gas chromatography.
Source:
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.